Risperidone treatment of motor restlessness following anoxic brain injury

Brain Injury

Volumn 17, Issue 3, 2003, Pages 237-244

  Silver, Bernard V ^a   Collins, Linda ^a   Zidek, Kathryn A ^a  

^a Institute for Rehabilitation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; METHYLPHENIDATE; PLACEBO; RISPERIDONE;

ADOLESCENT; ANOXIA; ARTICLE; ATTENTION; BRAIN INJURY; BURN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HEART ARREST; HOSPITAL DISCHARGE; HUMAN; LIGHTNING; LOW DRUG DOSE; MALE; MEDICAL PRACTICE; MENTAL TASK; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; RESTLESS LEGS SYNDROME; RESTLESSNESS; SEDATION; SIDE EFFECT; SKIN DISEASE; SPEECH THERAPY; WOUND HEALING;

EID: 0037333436     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/0269905021000013192     Document Type: Article

References (30)

1. Sandel, M. E. and Mysiw, J.: The agitated brain injured patient. Part 1: Definitions, differential diagnosis, and assessment. Archives of Physical Medicine Rehabilitation, 77: 617-623, 1996.
2. Boake C., Francisco, G. E., Ivanhoe, C. B. et al. Brain injury rehabilitation. Physical Medicine and Rehabilitation (Philadelphia: W.B Saunders), pp. 1073-1116, 2000.
3. Mysiw, W. J. and Sandel, M.E.: The agitated brain injured patient. Part 2: Pathophysiology and treatment. Archives of Physical Medicine Rehabilitation, 78, 213-220, 1997.
4. Fugate, L. P., Spacek, L. A., Kresty, L. A. et al.: Measurement and treatment of agitation following brain injury: II. A survey of the Brain Injury Interest Group of the American Academy of Physical Medicine and Rehabilitation. Archives of Physical Medicine Rehabilitation, 78: 924-928, 1997.
5. Leysen, J. E., Janssen, P. M. F., Megens, A. A. H. et al.: Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry, 55 (supl. 5): 5-12, 1994.
6. Green, B.: Focus on risperidone. Current Medicine Research Opinion, 16: 57-65, 2000.
7. Marder, S. R., Davis, J. M. and Chouinard, G.: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American Trials. Journal of Clinical Psychiatry, 58: 538-546, 1997.
8. Chouinard, G., Kopala, L., Labelle, A. et al.: The RIS-CAN-3 Study Group. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. Canadian Journal of Psychiatry, 43: 1018-1025, 1998.
9. Aleman, A. and Kahn, R. S.: Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: A meta-analysis of controlled trials. European Neuropsychopharmacology, 11: 289-293, 2001.
10. De Deyn, P. P., Rabher, U, K., Rasmussen, A. et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53: 946-955, 1999.
11. Katz, L. R., Jeste, D. V., Mintzer, J. E. et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Journal of Clinical Psychiatry, 60: 107-115, 1999.
12. Rainer, M. K., Masching, A. J., Ertl, M. G. et al.: Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. Journal of Clinical Psychiatry, 62: 894-900, 2001.
13. McDougle, C. J., Holmes, J. P., Bronson, M. R et al.: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36: 685-693, 1997.
14. McDougle, C. J., Holmes, J. P., Carlson, D. G. et al.: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55: 633-641, 1998.
15. Zarcone, J. R., Hellings, J. A., Crandall, K. et al.: Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation, 106: 525-538, 2001.
16. Schreiber, S., Klag, E., Gross, Y. et al.: Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. International Clinical Psychopharmacology, 13: 273-275, 1998.
17. Bates, J. B.: Effectiveness of risperidone in insatiable appetite following hypothalamic injury. Journal of Neuropsychiatry and Clinical Neuroscience, 9: 626, 1997.
18. Zimnitzky, B. M., Demaso, D. R. and Steingard, R. J.: Use of risperidone in psychotic disorder following ischemic brain damage. Journal of Child and Adolescent Psychopharmacology, 6: 75-78 1996.
19. Burnett, D. M., Kennedy, R. E., Cifu, D. X. et al.: Using atypical neuroleptic drugs to treat agitation in patients with a brain injury: A review. Neurorehabilitation, 13: 165-172, 1999.
20. Corrigan, J. D. Development of a scale for assessment of agitation following traumatic brain injury. Journal of Clinical and Experimental Neuropsychology, 11: 261-277, 1989.
21. Levin, H. S., O'Donnell, V. M. and Grossman, R. G.: The Galveston Orientation and Amnesia Test: A practical scale to assess cognition after head injury. Journal of Nervous and Mental Diseases, 167: 675-684, 1979.
22. Corrigan, J. D. and Bogner, J. A: Factor structure of the Agitated Behavior Scale. Journal of Clinical and Experimental Neuropsychology, 16: 386-392, 1994.
23. Addington, J. and Addington, D.: Neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol. Canadian Journal of Psychiatry, 42: 983, 1997.
24. Green, M. F., Marshall, B. D., Wirshing, W. C. et al.: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154: 799-804, 1997.
25. Weiser, M., Shneider-Beeri, M., Nakash, N. et al.: Improvement in cognition associated with novel antipsychotic drugs: A drug effect or reduction of EPS? Schizophrenia Research, 46: 81-89, 2000.
26. Haas, J. F. and Cope, D. N.: Neuropharmacologic management of behavior sequelae in head injury: A case report. Archives of Physical Medicine Rehabilitation, 66: 472-474, 1985.
27. Whyte, J.: Clinical drug evaluation. Journal of Head Trauma Rehabilitation, 3: 95-99, 1988.
28. Owens, D. G. C.: Extrapyramidal side effects and tolerability of risperidone: A review. Journal of Clinical Psychiatry, 55 (suppl. 5): 29-35, 1994.
29. Feeney, D. J. and Klykylo, W.: Risperidone and tardive dyskinesia. Journal of the American Academy of Child and Adolescent Psychiatry, 35: 1421-1422, 1996.
30. Kumar, S. and Malone, D. M.: Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgraduate Medicine Journal, 76: 316-317, 2000.